Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer

This publication has 18 references indexed in Scilit:

• Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors
  Anti-Cancer Drugs, 2006
• The importance of chemotherapy dose intensity in lung cancer
  Seminars in Oncology, 2004
• Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials
  Annals of Oncology, 2004
• Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
  JAMA, 2004
• Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration
  Current Opinion in Oncology, 2002
• Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study
  Annals of Oncology, 2001
• Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer
  British Journal of Cancer, 1996
• Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography
  Journal of Chromatography B: Biomedical Sciences and Applications, 1995
• A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
  Journal of Clinical Oncology, 1994
• Schedule-dependent topoisomerase II-inhibiting drugs
  Cancer Chemotherapy and Pharmacology, 1994